The nanoemulsion was developed at the University of Michigan and was then moved to a Biotech Company, NanoBio Corp, Ann Arbor, MI, for further development of applications and commercialization. One dermatologic application of nanoemulsion resulted in a successful treatment for Herpes Labialis, which are cold sores or fever blisters on the lips or surrounding skin that are predominantly caused by the Herpes simplex I (HSV1) virus.
NanoBio Corp. took the product development through Phase IIa & b trials. Next Phase results of this Herpes Labialis product will be published in October 2008.
Another application under development is an anti-infective for Genital Herpes, lesions of the genital area classically associated with Herpes simplex virus, type II (HSV-2).